The report in Human Reproduction shows that while ICSI use has levelled off in some regions, its use is approaching 100% of assisted reproduction cycles in the Middle East and a few countries in other regions, despite the fact that ICSI was developed for the treatment of male infertility, which is a factor in around 40% of couples seeking fertility treatment.
The world report covers the years 2008, 2009 and 2010 – the years for which the most recent data are available.
There was 1.4 times as much ICSI than IVF in Asia, twice as much in sub-Saharan Africa, just over twice as much in Europe, 2.7 times as much in North America, more than six times as much in Latin America and more than 60 times as much in the Middle East.
Doctors are guilty of over-estimating the effect of ICSI. The majority of the patients who will get pregnant with intracytoplasmic sperm injection (ICSI) will also do so with IVF.
Studies have shown that ICSI results in fewer live births than IVF when used for couples where male infertility is not the problem.
Intending to improve their patients’ pregnancy probability by preventing fertilization failure, well-meaning doctors actually decrease their chances. This has to stop. We have pledged to do no harm.
During the three years, more than 4,461,300 ART cycles were carried out, resulting in an estimated 1,144,858 babies born around the world. This represents a 9.5% increase in the number of cycles over the three years and a 9.1 increase in babies born.
The report shows wide variation in the use of ART between countries. Globally, ART use remained fairly constant, with 436 cycles per million of the population in 2008 and 474 cycles per million in 2010.
However, ART use ranged from 4,775 cycles per million in Israel (which had consistently the highest levels of access over the three years) to just eight cycles per million in the Dominican Republic in 2010.
In the same year there were almost 2,500 cycles per million in Australia and New Zealand, more than 900 per million in Europe, 570 cycles per million in North America, 150 cycles per million in Latin America and nearly 90 cycles per million in sub-Saharan Africa.
The global figure for the use of ART “conservatively represents less than 20% of the demand for ART treatment being met”.
The safety of ART improved, with an increase in the number of single embryos transferred per cycle. This increased from 25.7% in 2008 to 30% in 2010, while the average number of embryos transferred fell from 2.1 to 1.9 and the rates of twin and triplet births also fell.
The practice of freezing embryos and then thawing them and transferring them to women’s wombs (known as frozen embryo transfer or FET) also increased by 27.6% between 2008 and 2010; FET cycles had approximately half the multiple birth rate when compared with fresh embryo transfers, namely 13% (2008), 11.9% (2009) and 12% (2010), with just 0.6% triplet births in all three years.
Very importantly, however, SET is not a stand-alone practice or finding, but closely related to the cost patients pay for treatment, and to utilisation rates and the use of FET.
Supportive funding of ART, either through public or third party funding, increases utilisation through the provision of more affordable ART treatment, and at the same time encourages SET, which in turn allows for the freezing of excess embryos.
This means patients and doctors are under less pressure to maximise the immediate chance of pregnancy by transferring more than one embryo, which comes with the risk of multiple pregnancy.
The global multiple birth rate of 21.5% in 2010 is still too high, and policy and practice should seek to reduce the multiple birth rates.